# FDA 483 - Aditya Bardia, M.D. - August 17, 2018

Source: https://www.keypedia.com/records/483/aditya-bardia-md/220b0e7e-8eb5-4447-ab5d-bcecea4fea8e

> FDA 483 for Aditya Bardia, M.D. on August 17, 2018. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Aditya Bardia, M.D.
- Inspection Date: 2018-08-17
- Product Type: drugs
- Office Name: Division of Northeast Imports 
- Summary: An FDA inspection of Aditya Bardia, M.D. in Boston, MA, identified a significant deviation in the conduct of a clinical trial. The firm failed to follow its investigational plan by not reporting specific subject conditions and responses as mandated by the study protocol. This indicates a serious lapse in adherence to clinical trial procedures.

## Related Documents

- [483 - 2021-02-08](https://www.keypedia.com/records/483/aditya-bardia-md/47fdf899-db2d-4ca9-bead-96d59ec78a77)

## Related Officers

- [Matthew C. Watson](https://www.keypedia.com/people/matthew-c-watson/a1594b84-f65a-42f9-a06d-a68a49eb4b28)

Company: https://www.keypedia.com/companies/aditya-bardia-md/e2d6eaff-4279-4e74-b614-0455933f7b91

Office: https://www.keypedia.com/offices/division-of-northeast-imports/b20599cf-9797-41fd-947f-6589ef596a94